Printer Friendly

IMMUNEX ELECTS TOM MIZELLE VICE PRESIDENT, SALES AND MARKETING

 IMMUNEX ELECTS TOM MIZELLE VICE PRESIDENT, SALES AND MARKETING
 SEATTLE, July 21 /PRNewswire/ -- Immunex Corp. (NASDAQ: IMNX) today announced the election of Thomas Mizelle to the position of vice president, sales and marketing. He was formerly director of sales for the company.
 Before joining Immunex in May 1990, Mizelle was director of sales and marketing for Seattle-based NeoRx, where he planned the launch of that company's cancer-imaging product. Previously, he served as director of sales for Adria Laboratories in Columbus, Ohio, where he led the sales effort for that company's brand of doxorubicin, one of the world's most widely-prescribed anti-cancer agents.
 "Tom has built a world-class oncology sales organization that is widely recognized as one of our industry's finest," said Immunex President Michael Kranda. "He will play a critical role in helping to expand our line of oncology products, including our newest oncology product undergoing development and clinical trials, PIXIKINE (PIXY321). Tom will also develop marketing programs for our receptor products which may be useful in treating a variety of autoimmune and inflammatory diseases."
 Immunex Corp. is a biopharmaceutical company focused on the discovery, development, manufacture and marketing of products to treat cancer and autoimmune diseases.
 -0- 7/21/92
 /CONTACT: Jason Rubin or Mary McConnon of Immunex, 206-587-0430/
 (IMNX) CO: Immunex Corp. ST: Washington IN: MTC SU: PER


LM -- SE007 -- 1317 07/21/92 12:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 21, 1992
Words:228
Previous Article:GENSIA HIRES NEW RESEARCH DIRECTORS IN CENTRAL NERVOUS SYSTEM PHARMACOLOGY AND IMMUNOLOGY
Next Article:AMERICAN BRANDS REPORTS RECORD SECOND QUARTER WITH NET AND E.P.S. UP 9 PERCENT
Topics:


Related Articles
IMMUNEX ELECTS TOM ALBERG DIRECTOR
CYANAMID AND IMMUNEX FORM NEW BIOPHARMACEUTICAL COMPANY; MERGER APPROVED BY IMMUNEX STOCKHOLDERS
/C O R R E C T I O N -- IMMUNEX/
IMMUNEX NAMES TWO OFFICERS
IMMUNEX ANNOUNCES EXECUTIVE LEVEL CHANGES
Immunex and Medarex Announce Broad HuMAb-Mouse Licensing Agreement.
Immunex Corporation and Genentech, Inc. Join Forces to Develop TRAIL/Apo2L in Cancer.
Peggy Phillips is New Chief Operating Officer for Immunex Corporation.
Three Franchise Leaders Tapped for Promotions as Immunex Strengthens Commercial Operations Structure.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters